Related content

Hydroxylation of R (+)- and S (−)-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes

By Shiohira Hideo  

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2310-2316

Springer Publishing Company

Access to resources Recommend Favorite

Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese

By Yasumori T.   Narita H.   Matsuda T.   Takubo T.   Ogawa M.   Ishii M.   Hara K.   Ishii Y.   Okuyama K.   Fujimoto G.   Ochiai H.   Kano A.   Hasegawa S.   Sato K.   Taniguchi T.  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 11, 2006-11 ,pp. : 939-946

Springer Publishing Company

Access to resources Recommend Favorite

Comparative Bioavailability Study of Two Oral Omeprazole Formulations after Single and Repeated Administrations in Healthy Volunteers

By Duvauchelle T.  

Clinical Drug Investigation, Vol. 16, Iss. 2, 1998-08 ,pp. : 141-149

Adis International

Access to resources Recommend Favorite

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes

By Miura M.   Tada H.   Yasui-Furukori N.   Uno T.   Sugawara K.   Tateishi T.   Suzuki T.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 9, 2004-11 ,pp. : 623-628

Springer Publishing Company

Access to resources Recommend Favorite

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite